More than Money: Circassia
Circassia (LON: CIR) is a rare example of a small drug maker with a plan B for when drugs trials go wrong. That plan B (use its strong commercial platform to sell respiratory drugs globally) has now landed it with a second drug approval in the US and a label expansion which leaves its first US drug as the best-in-class for patients with chronic obstructive pulmonary disease (COPD). It has been ten months since Circassia filed for approval and the group’s chief executive Steve Harris was all ready to enjoy a well-earned holiday when both approvals came through on Friday. But he was still able to take some time out from his break to talk me through the good news.
Sign up for more great content
Register to continue reading our content.
Get FREE access now
Already a member? Login